Morningstar analyst Karen Andersen told Reuters that it might be a legal red line. Thumb on the scales: On Friday, the FDA released a statement name-checking Hims & Hers, saying it intended to take decisive steps against it and other compounding pharmacies using GLP-1 active ingredients to make alternatives to FDA-approved drugs, and warned that legal action without further notice might be headed their way
Studies also show that younger patients are more likely to relapse than older patients
Some of them, like selenium, zinc, vitamin E, C, beta-carotene and sulfur, exert an important antioxidant activity themselves or as cofactors of antioxidant enzymes, like glutathione peroxidase, superoxide dismutase and catalase
The ultimate winner in this space will be a GLP-1 agonist that delivers sustained clinical benefits with an excellent long-term safety profile and minimal adverse effects